CN1739791A - 肝细胞癌的预防及治疗 - Google Patents

肝细胞癌的预防及治疗 Download PDF

Info

Publication number
CN1739791A
CN1739791A CNA2005100915162A CN200510091516A CN1739791A CN 1739791 A CN1739791 A CN 1739791A CN A2005100915162 A CNA2005100915162 A CN A2005100915162A CN 200510091516 A CN200510091516 A CN 200510091516A CN 1739791 A CN1739791 A CN 1739791A
Authority
CN
China
Prior art keywords
seq
position residue
alpha
fetoprotein
peptide
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CNA2005100915162A
Other languages
English (en)
Chinese (zh)
Inventor
J·S·艾克挪茅
L·H·巴特菲尔德
A·李巴斯布鲁格拉
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of California, San Diego
Original Assignee
University of California, San Diego
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of California, San Diego filed Critical University of California, San Diego
Publication of CN1739791A publication Critical patent/CN1739791A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4715—Pregnancy proteins, e.g. placenta proteins, alpha-feto-protein, pregnancy specific beta glycoprotein
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Reproductive Health (AREA)
  • Toxicology (AREA)
  • Pregnancy & Childbirth (AREA)
  • Gynecology & Obstetrics (AREA)
  • Epidemiology (AREA)
  • Oncology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
CNA2005100915162A 1997-02-13 1998-02-13 肝细胞癌的预防及治疗 Pending CN1739791A (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US3837597P 1997-02-13 1997-02-13
US60/038,375 1997-02-13

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
CNB988052288A Division CN1222536C (zh) 1997-02-13 1998-02-13 肝细胞癌的预防及治疗

Publications (1)

Publication Number Publication Date
CN1739791A true CN1739791A (zh) 2006-03-01

Family

ID=21899585

Family Applications (2)

Application Number Title Priority Date Filing Date
CNA2005100915162A Pending CN1739791A (zh) 1997-02-13 1998-02-13 肝细胞癌的预防及治疗
CNB988052288A Expired - Lifetime CN1222536C (zh) 1997-02-13 1998-02-13 肝细胞癌的预防及治疗

Family Applications After (1)

Application Number Title Priority Date Filing Date
CNB988052288A Expired - Lifetime CN1222536C (zh) 1997-02-13 1998-02-13 肝细胞癌的预防及治疗

Country Status (8)

Country Link
US (1) US20020031520A1 (cg-RX-API-DMAC10.html)
EP (1) EP0979239B1 (cg-RX-API-DMAC10.html)
JP (3) JP3816959B2 (cg-RX-API-DMAC10.html)
KR (1) KR100460583B1 (cg-RX-API-DMAC10.html)
CN (2) CN1739791A (cg-RX-API-DMAC10.html)
AU (1) AU6435398A (cg-RX-API-DMAC10.html)
DE (1) DE69836209D1 (cg-RX-API-DMAC10.html)
WO (1) WO1998035981A1 (cg-RX-API-DMAC10.html)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN105126074A (zh) * 2015-09-30 2015-12-09 中国药科大学 多肽afp12在制备抗肿瘤药物中的应用

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR100482920B1 (ko) * 2000-02-10 2005-04-14 더 리젠츠 오브 더 유니버시티 오브 캘리포니아 간세포암을 치료하기 위한 조성물
FI118263B (fi) * 2002-10-09 2007-09-14 Timo Kalevi Korpela Kaspaasiaktiivisuutta säätelevät peptidit
US8932829B2 (en) 2005-07-07 2015-01-13 Elena Dudich Recombinant alpha-fetoprotein and compositions thereof
GB0617564D0 (en) * 2006-09-06 2006-10-18 Ucl Business Plc Peptides and methods
KR100900742B1 (ko) * 2007-05-17 2009-06-08 크레아젠 주식회사 인간 간암 동물모델 및 이를 이용한 수지상세포-유래 간암면역치료제의 예방 및 치료 효능을 분석하는 방법
WO2011048503A2 (en) * 2009-10-22 2011-04-28 Moro Ricardo J Peptides that bind the alpha-fetoprotein (afp) receptor and uses thereof
SG11201504558TA (en) 2012-12-11 2015-07-30 Einstein Coll Med Methods for high throughput receptor:ligand identification
CN114456272A (zh) 2015-04-03 2022-05-10 优瑞科生物技术公司 靶向afp肽/mhc复合体的构建体及其用途
CN105524884A (zh) * 2016-02-29 2016-04-27 时宏珍 Hla-a0201限制性抗afp抗原特异性ctl的制备方法
SG11201808552XA (en) 2016-05-18 2018-10-30 Cue Biopharma Inc T-cell modulatory multimeric polypeptides and methods of use thereof
IL262606B2 (en) 2016-05-18 2023-04-01 Albert Einstein College Medicine Inc pd-l1 variant polypeptides, T-cell modulatory multimeric polypeptides, and methods of using them
CN110325205B (zh) 2016-12-22 2023-08-15 库尔生物制药有限公司 T细胞调节性多聚体多肽及其使用方法
US11851471B2 (en) 2017-01-09 2023-12-26 Cue Biopharma, Inc. T-cell modulatory multimeric polypeptides and methods of use thereof
KR20240005989A (ko) 2017-03-15 2024-01-12 큐 바이오파마, 인크. 면역 반응을 조절하는 방법
WO2019139896A1 (en) 2018-01-09 2019-07-18 Cue Biopharma, Inc. Multimeric t-cell modulatory polypeptides and methods of use thereof
IL296209A (en) 2020-05-12 2022-11-01 Cue Biopharma Inc Multimeric t-cell modulatory polypeptides and methods of using them
JP2023541366A (ja) 2020-09-09 2023-10-02 キュー バイオファーマ， インコーポレイテッド １型真性糖尿病（ｔ１ｄ）を治療するためのｍｈｃクラスｉｉ ｔ細胞調節多量体ポリペプチド及びその使用方法
CN113416729B (zh) * 2021-05-18 2022-11-22 遵义医科大学附属医院 一种肝脏靶向调控甲胎蛋白基因的shRNA和cDNA及其应用

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH025866A (ja) * 1988-06-27 1990-01-10 Kansai Shin Gijutsu Kenkyusho:Kk ヒトアルファフェトプロテインドメインｉ遺伝子、対応プラスミド組換体、対応形質転換体、該ドメインｉの製造法及び製造された該ドメインｉ
IT1226551B (it) * 1988-07-29 1991-01-24 Sclavo Spa Peptide sintetico immunologicamente attivo capace di indurre la produzione di anticorpi con elevata specificita' verso l'alfa- fetoproteina e loro impiego in campo diagnostico
US5633234A (en) * 1993-01-22 1997-05-27 The Johns Hopkins University Lysosomal targeting of immunogens
US5593972A (en) * 1993-01-26 1997-01-14 The Wistar Institute Genetic immunization
AU700975B2 (en) * 1995-01-24 1999-01-14 Merrimack Pharmaceuticals, Inc. Recombinant human alpha-fetoprotein and uses thereof

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN105126074A (zh) * 2015-09-30 2015-12-09 中国药科大学 多肽afp12在制备抗肿瘤药物中的应用

Also Published As

Publication number Publication date
JP2001515347A (ja) 2001-09-18
EP0979239A4 (en) 2002-09-18
DE69836209D1 (de) 2006-11-30
AU6435398A (en) 1998-09-08
CN1259139A (zh) 2000-07-05
US20020031520A1 (en) 2002-03-14
WO1998035981A1 (en) 1998-08-20
EP0979239A1 (en) 2000-02-16
KR100460583B1 (ko) 2004-12-08
JP2010222379A (ja) 2010-10-07
EP0979239B1 (en) 2006-10-18
CN1222536C (zh) 2005-10-12
JP3816959B2 (ja) 2006-08-30
JP2006188528A (ja) 2006-07-20
KR20000071226A (ko) 2000-11-25

Similar Documents

Publication Publication Date Title
CN1178956C (zh) 基于癌抑制基因wt1的产物的癌抗原
CN1222536C (zh) 肝细胞癌的预防及治疗
CN1313773A (zh) 来自端粒酶的抗原性肽
CN1175954A (zh) 由hla分子提呈的分离的九肽及其应用
CN1520311A (zh) 含有基于癌抑制基因wt1的产物的癌抗原和阳离子脂质体的癌疫苗
CN100347191C (zh) 新mhcⅱ相关肽
CN1203177C (zh) 肿瘤抗原蛋白质及其基因和肿瘤抗原肽
CN1240834C (zh) Ly6h基因
CN1452634A (zh) Hla结合肽及其用途
CN1110503C (zh) 编码gage肿瘤排斥抗原的分离的截短的核酸分子
CN1209876A (zh) 分离的酪氨酸酶衍生肽及其应用
CN1169966C (zh) 酪氨酸酶衍生的分离肽及其应用
CN1218512A (zh) 用于人类肿瘤基因治疗的重组腺病毒载体
CN1264980C (zh) 新型肿瘤抗原蛋白sart－3及其肿瘤抗原肽
CN1784424A (zh) 编码人癌胚抗原的合成基因及其用途
CN1255427C (zh) 用于治疗肝细胞癌的方法和组合物
CN1244595C (zh) 一种肿瘤抑制蛋白及其应用
CN1948333A (zh) 一种新的hPEBP4蛋白来源的HLA－A2限制性表位多肽及其应用
CN1262562C (zh) 来源于sart－1的hla－a2限制性肿瘤抗原肽
CN1119169C (zh) 由hla－b44分子提呈的肿瘤排斥抗原及其应用
CN1289524C (zh) 一种人端粒酶活性抑制蛋白及其应用
CN1212398C (zh) 新型ifn受体1结合蛋白质,编码它们的dna,以及调节细胞对干扰素的反应的方法
CN1948342A (zh) 一种新的候选癌基因hRabJ来源的HLA－A2限制性表位多肽及其应用
CN1548455A (zh) 一种肿瘤抗原蛋白质和肿瘤抗原肽
CN1869064A (zh) 一种肿瘤抗原蛋白质和肿瘤抗原肽

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C02 Deemed withdrawal of patent application after publication (patent law 2001)
WD01 Invention patent application deemed withdrawn after publication